advertisement
Bourne R 16
Showing records 1 to 16 |
Display all abstracts from Bourne R98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucomaGhanchi F
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic reviewMarques AP
EClinicalMedicine 2022; 46: 101354
98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic populationGruzei C
International Ophthalmology 2022; 42: 785-797
99265 The economics of vision impairment and its leading causes: A systematic reviewRamke J
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucomaBourne R
Eye 2022; 36: 1154-1167
98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic populationZhang J
International Ophthalmology 2022; 42: 785-797
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucomaDownes SM
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic reviewCairns J
EClinicalMedicine 2022; 46: 101354
98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic populationBourne R
International Ophthalmology 2022; 42: 785-797
99265 The economics of vision impairment and its leading causes: A systematic reviewButt T
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucomaGale R; Rennie C
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic reviewZhang JH
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucomaTapply I
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic reviewJones I; Jovic M
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucomaSivaprasad S
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic reviewNandakumar A; Faal H; Taylor H; Bastawrous A; Braithwaite T; Resnikoff S; Khaw PT; Bourne R; Gordon I; Frick K; Burton MJ
EClinicalMedicine 2022; 46: 101354
Issue 22-4
Change Issue
advertisement